Waystar Sees 91.7% Upside with $46 Consensus Target; Earnings Growth Expected
Analysts maintain a bullish stance on Waystar with a $46 consensus target implying 91.7% upside and Leerink initiating coverage with a $43 price objective following its Iodine deal and AI expansion. Wall Street forecasts next week’s earnings growth after the stock fell 30.7% to a 52-week low of $28.08.
1. Analyst Targets and Sentiment
As of February 5, analysts set a $46 consensus target implying 91.7% upside on Waystar and Leerink initiated coverage on February 2 with an Outperform rating and $43 price objective, highlighting the company’s Iodine acquisition and expanding AI capabilities.
2. Stock Performance
Waystar’s shares have declined 30.7% over the past year, hitting a 52-week low of $28.08 on January 28 as market valuation lagged its technology-led expansion and customer penetration.
3. Earnings Outlook
Waystar is scheduled to report fourth-quarter and fiscal 2025 results next week, with Wall Street forecasting earnings growth and a potential beat in its upcoming earnings announcement.
4. Company Profile and Growth Drivers
The company provides cloud-based software for healthcare payment processing and revenue cycle management, leveraging a broad market reach, cross-selling opportunities, and AI-enhanced end-to-end platform to drive future growth.